Search PubMed⌕ Search

Biomedical subjects

L G Skinner

Publications and source records attributed to L G Skinner.

17 recordsLinked to original sources
PubMed1982

Isoelectric focusing of oestradiol receptor protein from human mammary carcinoma--a comparison with dextran coated charcoal assay.

Two simple methods for the detection of specific oestradiol--17 beta protein in breast tumour tissue were investigated. Isoelectric focusing of receptor protein in polyacrylamide gel was examined as an alternative micromethod to dextran-coated charcoal receptor assay. In a series of 32 cytosols prepared from unselected breast tumour tissue, assay results agreed on the presence or absence of receptors in 97% of cases. Quantitative analysis of the positive results showed a correlation coefficient, r = 0.88. Isoelectric focusing gave significantly lower receptor concentrations than the dextran-coated charcoal method. Twenty-six Tru-Cut biopsy tumour specimens were analyzed for receptor by isoelectric focusing and the results were compared with those obtained by the dextran-coated charcoal method on the same tumour. In 88% of the specimens examined, both methods agreed as to the presence or absence of receptor protein. A correlation coefficient, r = 0.62, was calculated from the 15 positive results. There was no significant difference between the results from the two methods. Quantitative results were related to total protein concentration in the cytosol. Negative receptor status was defined as less than 5 fmol/mg cytosol protein for both methods.

Breast Neoplasms↗
PubMed1980

The clinical value of multiple steroid receptor assays in breast cancer management.

Measurement of cytoplasmic estrogen (REc) and progesterone (RPc) receptors in human breast tumors together with estrogen receptor activity in the residual pellet ("nuclear" REN) provides a more accurate prediction of hormonal dependence that REc alone. Of 74 patients with advanced metastatic breast cancer, 57% of those with REc+ tumors had an objective response to endocrine manipulation. Of 51 patients whose tumor was assayed for both REc and RPc activity, 9 of 12 patients with REc+ RPc+ tumors showed remission, whereas only 3 of 30 patients with REc- RPc-, 2 of 6 with REc+ RPc-, and 2 of 3 with REc- RPc+ tumors had a clinical response. In a group of 19 patients where triple assay was performed, 5 of 6 with tumors positive for all three receptors responded, whereas 9 patients with triple negative tumors all showed no remission. Fifty-nine percent of primary and 60% of metastatic tumors with REc+ activity were also shown to be RPc+. Thirteen percent of REc- tumors were RPc+. Patients with REc+ RPc+ primary tumors tended to have a longer disease-free interval than patients with RPc- tumors, irrespective of whether the tumors were REc+ or REc-. In the light of the possibility of employing receptor status of the primary tumor to predict hormonal responsiveness in subsequent recurrences, a comparison is made of receptor status measured in primary tumors and metastases.

Adult↗
PubMed1979

Triple hormone-receptor assay: a more accurate predictive tool for the treatment of advanced breast cancer?

In a group of 74 patients with advanced metastatic breast cancer, 57% of those with cytoplasmic oestrogen receptor activity in their tumours (REC+) showed a clinical response to endocrine therapy. Of 51 patients whose tumour was assayed for both REC and cytoplasmic progesterone (RPC) activity, 9/12 patients with REC+ RPC+ tumours responded to hormone treatment, whereas only 3/30 patients with REC-RPC-tumours had a clinical response. In a group of 19 patients in whom nuclear oestrogen receptor (REN) was also estimated in the pellets from tumour-tissue homogenates, 5/6 with tumours positive for all 3 receptors showed a clinical response. None of the 9 patients with triply negative tumours responded. Addition of the REN assay appears to reinforce the greater precision of prediction when RPC as well as REC are estimated in breast tumours.

Breast Neoplasms↗
PubMed1975

Sex hormones in breast disease.

Serum concentrations of oestradiol 17beta and progesterone were measured daily throughout one menstrual cycle in 32 normal women, 32 women with benign disease of the breast and 10 women with cancer of the breast. In normal women concentrations varied with age. Women with cysts had concentrations of oestradiol 17beta which were significantly higher than normal. In women with cancer the concentrations of oestradiol 17beta and progesterone were significantly higher than normal, but the difference was very small and much larger numbers of patients need to be studied. Concentrations of oestradiol 17beta and progesterone in postmenopausal women were consistently very low.

Adult↗
PubMed1974

Serum oestradiol-17 beta in women with benign and malignant breast disease.

Serum concentrations of oestradiol-17β were measured daily throughout one menstrual cycle in 32 normal women, 31 women with benign disease of the breast and 10 with cancer of the breast. The concentrations were found to differ significantly from normal in women with cysts and to a lesser extent in those with cancer of the breast. In 25 normal post-menopausal and in 27 post-menopausal women with cancer repeated assays disclosed consistently low levels of oestradiol-17β.

Adenofibroma↗
PubMed1974

Serum oestradiol-17 beta in normal women.

Serum concentrations of oestradiol-17β were measured by radio-immunoassay during 40 menstrual cycles from 38 normal premenopausal women. Repeated samples were studied from 25 normal postmenopausal women. The method was highly specific and extremely sensitive. In premenopausal women the pattern of serum oestradiol-17β was remarkably constant but the concentrations varied with age. Women in the fourth decade of life had significantly higher concentrations of oestradiol-17β than either younger or older women. In postmenopausal women the concentration of oestradiol-17β was consistently very low.

Adult↗